In 2016, ESTEVE started a major restructuring of its governing structure with the inclusion of four independent members on its Board of Directors, several proprietary directors gave up their places on the Board and all Board Comities were redefined. In line with the plan approved by the Group's Board, Albert Esteve will replace Joan Esteve as Chairman of the Board and announces the appointment of Staffan Schüberg as the group's Chief Executive Officer.

Joan Esteve, who assumed the presidency of the group in 2012, a critical transition period for the company, managed to reverse the negative trend and return the company to a sustainable growth path. In these five years, Joan Esteve has led some of the most relevant projects of the group, such as a global agreement for the development of several of its own research projects and fostered a globalization of the group with international sales now representing 70% of the group's sale.

In the words of Joan Esteve, "in 2012 I assumed the responsibility to chair the group at a difficult time and I now leave it to Albert, in whom we have placed our trust. Albert has proven his ability to successfully lead the executive organization during these years" Joan Esteve will continue to be involved in the project as member of the Board and Chairman of the General Shareholders' Meeting.

Albert Esteve, CEO and Vice-Chairman of the group, will assume the Chairmanship in January 2018, "This is a new challenge that I am facing with tremendous enthusiasm. Consolidating the best practices in corporate governance initiated under the leadership of Joan Esteve, preserving the values that he has always defended and have been his norm of action in the Board and to support the growth of the group are my priorities".

Staffan Schüberg will join ESTEVE on January 1, 2018 as Chief Executive Officer (CEO). He will lead the executive management of the Esteve Group of companies, including all of its business activities (chemical, R&D based pharmaceuticals and generics). Regarding the CEO appointment "We feel fortunate and are much honored to welcome Staffan Schüberg as the new executive leader of the Group" says Albert Esteve.

Staffan Schüberg has more than 20 years experience from multinational pharma and is joining from the Danish multinational company Lundbeck where he has held the position as Executive Vice President and Chief Commercial Officer of the group.

It is the intention of ESTEVE to continue advancing and applying the best practices of the Code of Good Corporate Governance, guaranteeing an independent and sustainable management of the business and focusing the attention on creating meaningful shareholder value.

 
Albert Esteve

Albert Esteve has a degree in Economic Science from the University of Barcelona, and holds a Diploma in Business Administration from the ESADE Business School and in Corporate Resource Management from the IMD (Lausanne, Switzerland).
He joined an ESTEVE subsidiary as Assistant to General Management after gaining some years' experience in the fine chemical pharmaceutical sector in Spain and working for a multinational pharmaceutical company in the USA. He was subsequently appointed member of the Group's Executive Committee and has been Chief Executive Officer of ESTEVE since 2011. In 2017 he was appointed Vice-Chairman of the Board and from 2018 he will replace Joan Esteve as Chairman of the group Board of Directors.

Staffan Schüberg

Staffan Schüberg holds a BA (Hons) in Business Administration from the London Guildhall University. He has spent most of his professional career at Lundbeck. During his long tenure with the company, he served in a variety of commercial positions and played an integral role in expanding Lundbeck's global business.
Schüberg began his career with H. Lundbeck A/S in 1994, serving in different commercial positions in South Africa and Sweden. After three years with the company, Mr. Schüberg worked briefly as an International Marketing Manager, respiratory therapies at Astra Draco AB in Sweden before returning to Lundbeck as an International Marketing Director for the company's psychiatry business unit. During this time, he helped launch key company products in both Europe and in the U.S. Subsequently, he launched and managed the company's business in Portugal, and in 2005, assumed the position of Regional Vice President for southern Europe before taking on all the major markets in Europe. In 2010, he was appointed President and Chairman of Lundbeck's US operation that more than tripled in size during his tenure. Since 2016, Schüberg has served as Executive Vice President and Chief Commercial Officer of the group. Lundbeck has a team of more than 5,000 employees in 55 countries and generated revenues totaling 2.1 billion Euros in 2016.